VYNE Therapeutics Inc.VYNENASDAQ
Loading
Price to Sales: Discounted ValuationCompressed
Percentile Rank40
3Y CAGR+34.1%
5Y CAGR+34.9%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
+34.1%/yr
vs +21.1%/yr prior
5Y CAGR
+34.9%/yr
Consistent
Acceleration
+13.1pp
Accelerating
Percentile
P40
Within normal range
vs 5Y Ago
4.5x
Strong expansion
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 43.53 | -84.7% |
| 2024 | 284.78 | +404.4% |
| 2023 | 56.45 | +213.0% |
| 2022 | 18.03 | -68.0% |
| 2021 | 56.38 | +477.7% |
| 2020 | 9.76 | -97.3% |
| 2019 | 355.49 | +4136.8% |
| 2018 | 8.39 | -93.5% |
| 2017 | 129.04 | -86.1% |
| 2016 | 928.02 | - |